| 前收市價 | 4.5500 |
| 開市 | 4.5500 |
| 買盤 | 3.5000 |
| 賣出價 | 8.0000 |
| 拍板 | 9.00 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 4.5500 - 4.5500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
InvestorPlace7 F-Rated Stocks to Avoid at All Costs in June
For many people, the most important thing about investing is knowing which stocks to buy, and when to buy them. If you’re a buy-and-hold investor, then you’re going to keep your picks for a long time. If you’re a more active trader, then you’re also looking for the perfect time to take your profits and move on. It’s critically important for any investor to also be able to recognize which stocks to avoid – because those are the stocks that will wreck your portfolio if given the chance. This has b
ZacksVerastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
BenzingaWhat's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Thursday, Verastem Oncology (NASDAQ:VSTM) announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer. The initial interim results will be presented at the upcoming American Society of Clinical Oncology Annual Meeting. As of May 14, patients receiving the combination of avutometinib and defactinib with g
